Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis

British Journal of Cancer

Volumn 104, Issue 8, 2011, Pages 1278-1287

  Duiker, E W ^a   Meijer, A ^a   Van Der Bilt, A R M ^a   Meersma, G J ^a   Kooi, N ^a   Van Der Zee, A G J ^a   De Vries, E G ^a   De Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

apoptosis; caspase 8; cisplatin; DR5; p53; TRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 8; CISPLATIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DR5; PROTEIN P53; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME INDUCTION; ENZYME REGULATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA; CASPASE 8; CELL LINE, TUMOR; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UP-REGULATION;

EID: 79954448191     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.84     Document Type: Article

References (48)

1. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK (2008) Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiqui-tination in ovarian cancer cells. Cancer Res 68: 4511-4517
2. Abedini MR, Qiu Q, Yan X, Tsang BK (2004) Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23: 6997-7004 (Pubitemid 39319162)
3. Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3: 502-516 (Pubitemid 37328838)
4. Ashkenazi A, Holland P, Eckhardt SG (2008) Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apop-tosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630
5. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162
6. Baumler C, Duan F, Onel K, Rapaport B, Jhanwar S, Offit K, Elkon KB (2003) Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients. Leuk Res 27: 841-851 (Pubitemid 36683332)
7. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS (2004) Activation of caspases-8 and -10 by FLIP(L). Biochem J 382: 651-657
8. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR, Salvesen GS (2003) A unified model for apical caspase activation. Mol Cell 11: 529-541 (Pubitemid 36293843)
9. Chun HJ, Zheng L, Ahmad M, Wang J, Speirs CK, Siegel RM, Dale JK, Puck J, Davis J, Hall CG, Skoda-Smith S, Atkinson TP, Straus SE, Lenardo MJ (2002) Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419: 395-399
10. Crijns AP, Boezen HM, Schouten JP, Arts HJ, Hofstra RM, Willemse PH, Vries de EG, Van der Zee AG (2003) Prognostic factors in ovarian cancer: current evidence and future prospects. Eur J Cancer S1: 127-145 (Pubitemid 39345490)
11. Duiker EW, de Vries EG, Mahalingam D, Meersma GJ, Boersma-van EW, Hollema H, Lub-de Hooge MN, van Dam GM, Cool RH, Quax WJ, Samali A, van der Zee AG, de Jong S (2009) Enhanced antitumor efficacy of a DR5-specific TRAIL variant over recombinant human TRAIL in a bioluminescent ovarian cancer xenograft model. Clin Cancer Res 15: 2048-2057
12. Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, de Jong S, de Vries EG (2010) The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 116: 549-555
13. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498 (Pubitemid 32494397)
14. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK (2003) p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 63: 7081-7088 (Pubitemid 37413443)
15. Fulda S, Meyer E, Friesen C, Susin SA, Kroemer G, Debatin KM (2001) Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene 20: 1063-1075 (Pubitemid 32238855)
16. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H (2004) Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 11(Suppl 1): S86-S96 (Pubitemid 39136801)
17. Garofalo M, Quintavalle C, Di LG, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G (2008) MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 27: 3845-3855 (Pubitemid 351862062)
18. 0Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89: 3070-3074
19. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS (2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28: 2839-2846
20. Holcik M, Sonenberg N (2005) Translational control in stress and apoptosis. Nat Rev Mol Cell Biol 6: 318-327 (Pubitemid 40516898)
21. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N (2000) Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60: 4315-4319 (Pubitemid 32103601)
22. Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF, Hamilton TC (1994) Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem Pharmacol 47: 689-697 (Pubitemid 24094274)
23. Kent OA, Mendell JT (2006) A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes. Oncogene 25: 6188-6196 (Pubitemid 44527849)
24. Kim HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH (2003) Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 125: 708-715 (Pubitemid 37070689)
25. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E, manche-Boitrel MT (2003) Chemotherapy enhances TNF-related apop-tosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22: 1807-1816 (Pubitemid 36519144)
26. Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501 (Pubitemid 28391865)
27. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25: 838-848 (Pubitemid 43237702)
28. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A (2009) TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 35: 280-288
29. Martinez LA, Naguibneva I, Lehrmann H, Vervisch A, Tchenio T, Lozano G, Harel-Bellan A (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc Natl Acad Sci USA 99: 14849-14854 (Pubitemid 35334572)
30. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, Briand C, Grutter MG (2002) The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 277: 45162-45171 (Pubitemid 36159119)
31. Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP (2002) Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99: 2162-2171 (Pubitemid 34525502)
32. Ozaki T, Hosoda M, Miyazaki K, Hayashi S, Watanabe K, Nakagawa T, Nakagawara A (2005) Functional implication of p73 protein stability in neuronal cell survival and death. Cancer Lett 228: 29-35 (Pubitemid 41188421)
33. Peter ME (2000) The TRAIL DISCussion: it is FADD and caspase-8!. Cell Death Differ 7: 759-760
34. Peter ME (2004) The flip side of FLIP. Biochem J 382: e1-e3
35. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690 (Pubitemid 26175834)
36. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace Jr AJ, El-Deiry WS (1998) p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res 58: 1593-1598 (Pubitemid 28215076)
37. Soung YH, Lee JW, Kim SY, Sung YJ, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH (2005) Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225-1226delTG in hepatocellular carcinomas. Oncogene 24: 141-147 (Pubitemid 40143873)
38. Spierings DC, de Vries EG, Vellenga E, de Jong S (2003) Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10: 808-822 (Pubitemid 36850242)
39. Takita J, Yang HW, Chen YY, Hanada R, Yamamoto K, Teitz T, Kidd V, Hayashi Y (2001) Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene 20: 4424-4432 (Pubitemid 32726887)
40. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535 (Pubitemid 30305902)
41. Wernyj RP, Morin PJ (2004) Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat 7: 227-232 (Pubitemid 39469095)
42. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682 (Pubitemid 26091143)
43. Wu GS, Burns TF, McDonald III ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS (1997) KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 17: 141-143
44. Wu XX, Ogawa O, Kakehi Y (2004) TRAIL and chemotherapeutic drugs in cancer therapy. Vitam Horm 67: 365-383 (Pubitemid 39753671)
45. Xu Y (2003) Regulation of p53 responses by post-translational modifications. Cell Death Differ 10: 400-403 (Pubitemid 36626351)
46. 0Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 68: 425-433 (Pubitemid 351380068)
47. Zhang L, Zhu H, Teraishi F, Davis JJ, Guo W, Fan Z, Fang B (2005) Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. Neoplasia 7: 594-602 (Pubitemid 40967760)
48. Zhang XY, Zhang XD, Borrow JM, Nguyen T, Hersey P (2004) Translational control of tumor necrosis factor-related apoptosis-inducing ligand death receptor expression in melanoma cells. J Biol Chem 279: 10606-10614 (Pubitemid 38372672)